New hope for rare bone marrow diseases: drug tames immune attack
NCT ID NCT05998408
First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times
Summary
This study tests a pill called ruxolitinib for people whose immune system attacks their bone marrow, causing conditions like severe anemia. The drug aims to stop this attack and help the bone marrow recover. Participants take the pill twice daily for up to 6 months and are followed for 3 years. The goal is to see if the drug is safe and can improve blood counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPLASTIC MDS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Half-Matched stem cell transplant offers hope for children with blood disorders
- New transplant approach aims to tame bone marrow failure
- New hope for older adults with rare blood disorder: safer transplant regimen under study
- New drug combo shows promise for rare bone marrow failure
- New drug combo shows promise for rare blood disorder